重症COVID-19成人标准预防剂量与中间剂量依诺肝素的随机对照试验
这项多中心、开放标签、随机对照试验比较了重症COVID-19住院成人使用标准预防剂量与中间剂量依诺肝素的效果。176例患者随机分组,主要结局30天全因死亡率在中间剂量组为15%、标准剂量组为21%,差异无统计学意义。两组动脉或静脉血栓栓塞及大出血发生率相似。
要点
- 重症COVID-19住院成人中,中间剂量依诺肝素较标准预防剂量未显著降低30天全因死亡率。
- 两组动脉或静脉血栓栓塞及大出血发生率相近,安全性无显著差异。
- 标准预防剂量与中间剂量依诺肝素在预防死亡或血栓方面无显著差异。
核心结论
- 在重症COVID-19住院成人中,标准预防剂量与中间剂量依诺肝素在30天预防死亡或血栓方面无显著差异。
研究设计与样本
- 多中心、开放标签、随机对照试验,纳入176例(99男77女)重症COVID-19住院成人,1:1随机接受标准预防剂量或中间体重调整剂量依诺肝素。
主要发现
- 动脉或静脉血栓发生率中间剂量组为13%,标准剂量组为9%;大出血两组均为2%。
临床怎么用
- 对于重症COVID-19住院成人,标准预防剂量依诺肝素仍是合理选择,中间剂量未显示额外获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronavirus disease 2019 (COVID-19) is associated with coagulopathy but the optimal prophylactic anticoagulation therapy remains uncertain and may depend on COVID-19 severity. OBJECTIVE: To compare outcomes in hospitalized adults with severe COVID-19 treated with standard prophylactic versus intermediate dose enoxaparin. METHODS: We conducted a multi-center, open-label, randomized controlled trial comparing standard prophylactic dose versus intermediate dose enoxaparin in adults who were hospitalized with COVID-19 and admitted to an intensive care unit (ICU) and/or had laboratory evidence of coagulopathy. Patients were randomly assigned in a 1:1 ratio to receive standard prophylactic dose enoxaparin or intermediate weight-adjusted dose enoxaparin. The primary outcome was all-cause mortality at 30 days. Secondary outcomes included arterial or venous thromboembolism and major bleeding. RESULTS: A total of 176 patients (99 males and 77 females) underwent randomization. In the intention-to-treat population, all-cause mortality at 30 days was 15% for intermediate dose enoxaparin and 21% for standard prophylactic dose enoxaparin (odds ratio, 0.66; 95% confidence interval, 0.30-1.45; P = .31 by Chi-square test). Unadjusted Cox proportional hazards modeling demonstrated no significant difference in mortality between intermediate and standard dose enoxaparin (hazard ratio, 0.67; 95% confidence interval, 0.33-1.37; P = .28). Arterial or venous thrombosis occurred in 13% of patients assigned to intermediate dose enoxaparin and 9% of patients assigned to standard dose enoxaparin. Major bleeding occurred in 2% of patients in each arm. CONCLUSION: In hospitalized adults with severe COVID-19, standard prophylactic dose and intermediate dose enoxaparin did not differ significantly in preventing death or thrombosis at 30 days.
引用
- Perepu US, Chambers I, Wahab A, et al. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial. J Thromb Haemost. 2021. PMID: 34236768. doi:10.1111/jth.15450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。